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Introduction
The pharmaceutical industry has always sought to develop drugs
that meet the basic clinical needs of treating symptoms and
disease. Previously, many first-in-class drugs developed new
multi-billion-dollar markets by targeting large populations. Gaini
marketing authorisation was often synonymous with gaining1359-6446/ 2014 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativ
http://dx.doi.org/10.1016/j.drudis.2014.12.009 market; this is no longer a certainty. Today, most new drugs
compete against numerous therapies, including nonpharmaceu-
tical options. To create new value these therapies need to provide
benefits beyond existing therapies, and perhaps serve stakeholders
differently to the prescribing physician and patient.
Looking for new value, pharma organizations have invested in
identifying patient subgroups with superior biological responses
to a specific new molecular entity [1,2]. Numerous investments
focus on identifying novel biomarkers and companion diagnostics
for personalized medicine [1]. Astonishing technical develop-
ments (genomics, proteomics, metabolomics) have fueled bio-
marker research [3,4], but progress is slow [5]. Until the tools of
research improve, pharma companies need other ways to boost
pharmaceutical productivity and create value; modern design
methods might serve this role.
The pharma industry is not the first maturing industry to experi-
ence gradual commoditization, shifting customer requirements and
pressures to increase productivity (information technologies once
created value through technical performance, but now promote
ease of use, mobility and connectivity). Complementary to finding
biomarkers and companion diagnostics, one can create value by
deeply understanding the context of use of new products. Person-
alized medicine which recognizes the individual characteristics of
each patient certainly considers all the elements of patient care
when tailoring individual treatment: usability, access, affordability,
among others. Thus, knowledge and insights gained from human-
centered research could provide keys for creating unique value.
Because investments in personalized medicine are driven partly
by new demands from consumers, taking a human-centered ap-
proach to value creation makes sense. Patients desire treatments
that integrate into their lifestyles and serve their aspirations (Fig. 1).
This is consistent with known hierarchies of need [6] where early
solutions meet basic requirements. Today, there are many new
needs and stakeholders: caregivers have important roles; new buyers
seek sensible alternatives; physicians want patients to succeed
(against burdens of training, complexity and adherence). In addi-
tion, health authorities can update standards for safety and efficacy.
Adjacent to the insights for R&D provided by biomarkers,
there are numerous human-centered insights that pertain to indi-
viduals, including knowledge of lifestyle preferences, care-givingecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 1
In today’s healthcare market the customer measures success in more ways
than clinical outcomes. Despite large investments in R&D it has proven difficult
for many pharma companies to meet the increased demands for drugs that
integrate well into specific lifestyle and support patient aspirations to live
normal lives.
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effects and co-morbidities. Biomarkers and human-centered insights
can figure into a target drug profile and guide development; for
example recognizing that giving medication to a pre-teen child
could guide developers toward a dosing format suitable for children’s
tastes and bodies, as well as parent and/or school schedules. Addres-
sing such factors in discovery and development can significantly
increase market acceptance; neglecting these factors could squander
a drug’s potential. Given the changing landscape of healthcare, and
new demands from users and health systems, successful future drugs
will integrate attributes from biomarkers and human-centered
insights to provide optimal benefits for stakeholders. There is evi-
dence that this approach can create value (Box 1).
Human-centered research can guide development and
increase productivity
The challenge exists to translate human insights into products and
features, and to incorporate insights much earlier in
the development process. The goal is to focus research (greater
efficiency during development) and establish real value when the
molecule reaches the market (greater demand by meeting real
needs). Just as the identification of biomarkers can lead to quanti-
fiable tests and indicators, the identification of human-centered
insights can suggest valuable characteristics of a new drug. These
human insights can be subjective and qualitative in nature, in-
cluding the insights mentioned previously, along with user pre-
ferences about style, mobility and social behavior.
The human-centered design process can reveal
opportunity
Human-centered design research can uncover what is really mean-
ingful to people – their needs, desires and aspirations – by testing
and clarifying assumptions about users. Whereas the purpose of290 www.drugdiscoverytoday.commost scientific research is validation of a hypothesis (or endpoint),
design research typically seeks inspiration by collecting new per-
spectives (for later validation). The outcomes of design research are
often new hypotheses about human behaviors and needs, which
developers can probe. Scientific and analytical methods are excel-
lent tools when only assumptions are clear. When assumptions are
less clear, as is often the case with human issues or unfamiliar
innovations, design tools offer a strong way to clarify assumptions
and gain qualitative understanding of issues – and thus efficiently
focus future analysis [7,8].
The human-centered design process starts with deep empathy
for users, and concrete data from interviews and observations. In-
field observations overcome prejudices, clarify context and collect
detailed stories and evidence. Specific, vivid stories – not abstract-
ed summaries – can produce original insights, even with very small
user samples (a user sample of n = 1 is sufficient to illustrate that
medications for arthritis should not require a strong grip). Empa-
thetic observations help avoid pitfalls that are well known to user
researchers: that people often do not (i) do what they are expected
to do, (ii) do what they are told to do or (iii) do what they say they
did. From the user stories, the design process abstracts themes,
principles and frameworks that describe the world of users, creat-
ing actionable scenarios of opportunity. After forming hypotheses,
the designer will create prototypes, experiments and storyboards
of promising concrete concepts that researchers can bring back to
users to confirm their value – or build better ideas. The process is
iterative, generating many ideas and constantly improving them
with new evidence from user feedback.
The identification of human-centered indicators of value might
start with a promising molecular pathway that acts on a biological
system (hunger, weight, metabolism). From this, one can postulate
successful drug profiles, and then build stories about how these drugs
integrate into the lives of all the stakeholders. Sharing these stories
with patients, caregivers and physicians is a rapid, low-risk way to
collect feedback about the potential impact of an idea, and what
specific product features are necessary to create this impact and
value.
User-research can have a bottom-up or top-down
human-centered focus
The bottom-up approach relies on early discussions and ‘probes’
with potential users to evaluate whether specific novel biological
targets could provide a real benefit to specific users. The top-down
approach requires user research to define new, attractive oppor-
tunities within a targeted customer segment. With user data,
teams can define and direct research platforms to identify mole-
cules affecting a biological pathway that could provide the desired
benefit. Both approaches collect evidence about:
 the patient’s daily life, challenges and concerns;
 how the patient and caregivers manage the disease (and co-
morbidities);
 current alternative therapies and their limitations (including
nonpharma therapies);
 common problems for patients and/or caregivers, and popular
‘work-arounds’.
In the bottom-up approach, including human-centered criteria
throughout discovery and development creates confidence that the
science remains relevant for potential users, and that discoveries will
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BOX 1
An example where a deep understanding of human
behaviors combined with biological insights is the
recently marketed class of glucagon-like peptide (GLP)-1
drugs for treatment of type 2 diabetes (T2D)
Exenatide, a twice-daily injection to control HbA1c (originally from
Amylin and Lilly), competed with oral treatment alternatives.
Despite being injectable, exenatide succeeded (partly by
promoting weight loss), generating over US$500 million in sales in
2011 (http://www.drugwatch.com/byetta/). Instead of shunning
injectables in favor of orals, patients were willing to inject
themselves twice daily, suggesting weight loss was also important
to users while lowering HbA1c [11]. Subsequently, many
companies accelerated development of their GLP-1 drugs, seeking
improved pharmacokinetic properties for once-daily or once-
weekly injection. Five years after exenatide, liraglutide (Novo
Nordisk) appeared as a once-daily injection, capturing a majority
share in many markets (http://www.drugwatch.com/victoza/). The
next generation of products includes once-weekly alternatives.
Time will tell if these products will capture significant market share
from the daily options, acknowledging the user desire for fewer
injections. Meanwhile, Sanofi launched once-daily lixisenatide
(licensed from Zealand Pharma) [12], the profile of which provides
significant postprandial glucose control [13], complementing basal
insulins that control fasting blood glucose. Before lixisenatide,
Sanofi had accumulated insights into patient and prescriber
behavior through LantusW (basal insulin glargine). Sanofi
understood the potential of lixisenatide regarding postprandial
glucose control, and also realized that many T2D patients on basal
insulin were reluctant to take mealtime insulin for additional
glucose control – and Sanofi targeted the development of
lixisenatide for these patients. Recognizing the favorable potential
of including a GLP-1 agonist with basal insulin, physicians have
prescribed this combination ‘off-label’ frequently (at lixisenatide
launch in Europe, 40% of all GLP-1 agonist prescriptions paired
with basal insulin). This early focus on human behaviors, combined
with biological insights, helped place lixisenatide in a different
competitive market to the providers of long-acting analogs.
Further, beyond offering longer-acting versions of GLP-1 agonists,
companies now focus on injections of the combination of once-
daily GLP-1 with basal insulin (http://www.ema.europa.eu/docs/
en_GB/document_library/Summary_of_opinion_-_Initial_
authorisation/human/002647/WC500170171.pdf, http://www.
sanofi.com/Images/33239_24062013_ADA_final_Web.pdf). This
solution holds great promise for patients on basal insulin who need
better glucose control, desire once-a-day injection or have
concerns about weight gain. Pharma companies developing novel
GLP-1 receptor agonists could have sought biological biomarkers
to predict patient-specific responses to each drug, or sought
formulations with fewer side-effects; however, the focus on human
needs created significant new value and better patient care.
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guarantee its value in today’s crowded marketplace). Teams can
refine these hypotheses throughout the discovery and development
process based on new evidence (user-research, feedback and emerg-
ing key biological data). User-research can suggest key product
attributes required for success – to differentiate a product among
competitors, to solve a previously unmet need or to integrate the use
of the product into someone’s lifestyle. Thus guided, teams can
focus on specific in vitro and in vivo experiments that could demon-
strate these promising specific attributes.A top-down human-centered approach might involve collect-
ing information about underserved needs among key customer
segments, uncovering unexpected needs among patients, physi-
cians and other stakeholders, and focusing research efforts to
identify molecules with specific attributes that serve these needs.
Data from the top-down process can guide initial target develop-
ment, opening potential research avenues, uncovering insights
from stakeholders outside the vision of an R&D organization and
suggesting radical collaborations. Such collaborations can increase
value through partnerships that bring new capabilities to pro-
ducts, and suggest strategies to coordinate care or share risk; a
strategy already adopted by several companies [9,10].
With either approach to human-centered research, the molecular
development process benefits from parallel human-centered re-
search throughout the discovery and development phase. This
suggests incorporating well-defined human-centered criteria and
milestones inside the product development process. These mile-
stones should co-exist with (not replace) existing business and
technical milestones.
Human-centered user research can (i) increase the productivity
of development teams by helping them choose the most useful
potential medicines when there are many alternatives and (ii) help
articulate real value to users for a given medicine. New value could
result from features and attributes that are different to purely
clinical results (i.e. attributes that support successful use, the
circumstances of care or integration into larger therapeutic plans).
By building a culture that supports human-centered research, R&D
organizations can significantly augment their tools for guiding
personalized medicine and create robust portfolios of products
that users strongly value.
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